Gilead ends RSV antiviral trials after low incidence ratesnews2025-06-26T19:04:57+00:00June 26th, 2025|Endpoints News|
CDC vaccine panel votes to remove thimerosal from flu shotsnews2025-06-26T18:36:33+00:00June 26th, 2025|Endpoints News|
Altimmune posts mixed results for incretin drug in MASH; stock is halvednews2025-06-26T15:22:50+00:00June 26th, 2025|Endpoints News|
Opus, Viatris say presbyopia drug succeeds in Phase 3news2025-06-26T14:22:07+00:00June 26th, 2025|Endpoints News|
Novartis strikes cardiovascular discovery deal with Flagship’s ProFoundnews2025-06-26T10:30:41+00:00June 26th, 2025|Endpoints News|
Endpoints Livestream: ACIP and the future of vaccinesnews2025-06-26T10:00:32+00:00June 26th, 2025|Endpoints News|
Ex-CBER chief Marks criticizes FDA vaccine framework processnews2025-06-25T21:00:28+00:00June 25th, 2025|Endpoints News|
ACIP will reassess cumulative vaccine effects, older shotsnews2025-06-25T19:37:34+00:00June 25th, 2025|Endpoints News|
Kymera inks deal with Gilead as partnership with Sanofi faces a switch-upnews2025-06-25T15:30:48+00:00June 25th, 2025|Endpoints News|
#ADA25: BrightGene seeks a partner for Zepbound-beating obesity shotnews2025-06-25T15:04:27+00:00June 25th, 2025|Endpoints News|
